Paid Partnership with LEO Pharma This isn't just dry skin... It could be chronic hand eczema.

@dermguru

1.7M followers · usually 61.3K views a post

Views

3.1M

Likes

1.9K

Comments

SoundTikTok sound · original sound - dermguru

Why it worked

The video effectively educates viewers about a common but often misunderstood skin condition (CHE) and presents a specific, FDA-approved treatment option. The dermatologist's expertise lends credibility, and the soft-sell approach, combined with clear visuals and a direct call to action, makes it informative and persuasive.

Summary

A dermatologist explains that persistent dry or itchy hands could be chronic hand eczema (CHE). She introduces ANZUPGO, a prescription cream that is the first FDA-approved treatment for moderate to severe CHE in adults who haven't responded to or can't use topical corticosteroids. The video highlights its benefits, potential side effects, and encourages viewers to visit anzupgo.com and consult a dermatologist.

Structure

1Introduction to chronic hand eczema (CHE)
2Explanation of CHE symptoms and impact on daily life
3Introduction of ANZUPGO as a treatment option
4Details on ANZUPGO's approval, target audience, and benefits
5Discussion of potential side effects and contraindications
6Call to action: visit anzupgo.com and consult a dermatologist

Product placement

LEO Pharma (appears as a watermark, removing it would not change what happens in the video); ANZUPGO (acts - it is a cream that is applied to the skin to treat eczema, removing it would change what happens in the video); delgocitinib (acts - it is the active ingredient in ANZUPGO, removing it would change what happens in the video)

Original caption

#ANZUPGOPartner #Ad Watch for important safety information. The more you know: chronic hand eczema (CHE) is WAY more common than you think, affecting about 1 in 10 adults. The good news? There is a steroid-free prescription treatment that can help! Enter ANZUPGO® (delgocitinib) cream 2%* the first and only FDA-approved treatment for adults with moderate-to-severe CHE who are not well-controlled with, or cannot use topical corticosteroids. The use of ANZUPGO along with other JAK inhibitors or strong immunosuppressants is not recommended. CHE can be highly visible, or have less obvious symptoms. Symptoms of CHE, such as redness and dryness, can progress to itchy, painful cracks and, sometimes in the most severe cases, even bleeding. If you're experiencing any CHE symptoms, I encourage you to make an appointment with a dermatologist to see if ANZUPGO may be right for you. #Sponsored by LEO Pharmaceuticals and intended for US audiences only. Please go to @anzupgo_delgocitinib for Important Safety Information, Patient Medication Guide, and Full Prescribing Information. *Prescription only

More from @dermguru

On-screen text

Paid Partnership with LEO Pharma This isn't just dry skin... It could be chronic hand eczema. Clinical trial patient IF YOUR HANDS ARE CONSTANTLY DRY OR ITCHY YOU MIGHT NOT JUST HAVE DRY SKIN Actor portrayal I'M A DERM AND FROM MY EXPERIENCE IT COULD BE CHRONIC HAND ECZEMA OR CHE IT'S ACTUALLY MORE COMMON THAN PEOPLE REALIZE AND IT CAN BE CONSIDERED CHE WITH AS LITTLE AS TWO FLARES A YEAR TRUST ME WHEN I SAY IT CAN MAKE DAILY THINGS LIKE WASHING YOUR HANDS DOING DISHES OR EVEN TYPING SUPER UNCOMFORTABLE HEAR ME OUT IF YOU HAVE TWO OR MORE FLARES OF HAND ECZEMA A YEAR THAT'S A SIGN TO TALK TO YOUR DERM CHE IS ITS OWN THING AND MAY NEED A MORE TARGETED APPROACH Actor portrayal SOMETHING I PRESCRIBE IN CLINIC FOR PATIENTS WITH RECURRING MODERATE TO SEVERE HAND ECZEMA IS ANZUPGO ECZEMA IS ANZUPGO (delgocitinib) ANZUPGO® (delgocitinib) cream 2% Actor portrayal ALSO KNOWN AS DELGOCITINIB ANZUPGO IS THE FIRST AND ONLY FDA APPROVED TREATMENT SPECIFICALLY FOR ADULTS WITH MODERATE TO SEVERE CHRONIC HAND ECZEMA Actor portrayal WHO ARE NOT WELL CONTROLLED WITH OR CANNOT USE TOPICAL CORTICOSTEROIDS Actor portrayal USE OF ANZUPGO ALONG WITH OTHER JAK INHIBITORS OR STRONG IMMUNOSUPPRESSANTS IS NOT RECOMMENDED IT'S A STEROID FREE PRESCRIPTION CREAM THAT MAY RESULT IN PATIENTS EXPERIENCING CLEAR Actor portrayal CLEAR SKIN ALONG WITH RELIEF FROM ITCH AND PAIN Actor portrayal PLUS IT'S NON GREASY AND FREE OF KNOWN Actor portrayal SENSITIZERS AND IRRITANTS IN STUDIES THE MOST COMMON SIDE EFFECTS REPORTED IN LESS THAN 1% OF ANZUPGO TREATED PATIENTS INCLUDE APPLICATION SITE REACTIONS INCLUDING PAIN TINGLING ITCHING AND REDNESS BACTERIAL SKIN INFECTIONS INCLUDING AND NAIL INFECTIONS LOW WHITE BLOOD CELLS THESE ARE NOT ALL OF THE POSSIBLE SIDE EFFECTS OF ANZUPGO OR THINK YOU MAY HAVE MODERATE TO SEVERE CHRONIC HAND ECZEMA I DEFINITELY RECOMMEND CHECKING OUT ANZUPGO.COM TO LEARN MORE AND MAKING AN APPOINTMENT WITH A DERMATOLOGIST TO SEE IF IT COULD BE A GOOD FIT FOR YOU Stay for more important safety info STAY TUNED FOR IMPORTANT SAFETY INFORMATION Prescription only ANZUPGO is for use on the skin only. Do not use in or on your eyes, mouth, or vagina. WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT ANZUPGO? ANZUPGO may increase your risk of infections because it contains delgocitinib, a type of medicine called a JAK inhibitor that can affect your immune system. Serious infections (including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses) have happened with JAK inhibitors. Some people have been hospitalized or died. Do not use ANZUPGO if you have an active, serious infection. Do not start ANZUPGO if you have any infection unless your healthcare provider says it's okay. You may be more likely to get shingles (herpes zoster) or eczema herpeticum (painful, blistering rash) during treatment. Before using ANZUPGO: Tell your healthcare provider if you: - are being treated for an infection or have an infection that does not go away or that keeps coming back - have TB or were in close contact with someone with TB - have had shingles - have had hepatitis B or C - have symptoms of infection such as fever, chills, sweating, muscle aches, cough/shortness of breath, blood in phlegm, weight loss, warm/red/painful skin or sores, diarrhea or stomach pain, burning when urinating or urinating more often, or feeling very tired After starting ANZUPGO: Call your healthcare provider right away if you have signs of infection. Your provider may stop ANZUPGO until the infection is controlled. ANZUPGO may increase the risk of certain skin cancers. Your healthcare provider will check your skin during treatment. - Avoid sunlamps, limit sun, wear protective clothing, and use broad-spectrum sunscreen. - Tell your healthcare provider if you have ever had any type of cancer. It is not known if ANZUPGO has the same risks as other JAK inhibitors. Increased risk of death (all causes) happened in people 50+ with at least one heart disease risk factor taking a JAK inhibitor for rheumatoid arthritis (RA) compared with TNF blockers. ANZUPGO is not for use in RA. Oral or other topical JAK inhibitors have also caused increased cholesterol. Low blood sugar in diabetics has happened after taking oral JAK inhibitors. Before using ANZUPGO: Tell your healthcare provider if you: - have an infection - have recently received or are scheduled to receive a vaccine. Do not receive live vaccines right before starting, during treatment, or right after treatment with ANZUPGO. - are pregnant or plan to become pregnant (it is not known if ANZUPGO will harm your unborn baby) - are or plan to breastfeed (it is not known if ANZUPGO passes into breast milk). Avoid touching the nipple/area around it right after applying ANZUPGO to your hands and wrists. The most common side effects were application site reactions, including pain, tingling, itching, and redness; bacterial skin infections, including finger cellulitis and nail infections; and low white blood cells. These are not all of the possible side effects of ANZUPGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please see full Prescribing Information and Medication Guide. The LEO Pharma logo and ANZUPGO are registered trademarks of LEO Pharma A/S. © 2023 LEO Pharma Inc. All rights reserved. MAT-97079 August 2023.

Transcript

If your hands are constantly dry or itchy, you might not just have dry skin. I'm a derm and from my experience, it could be chronic hand eczema or CHE. It's actually more common than people realize and it can be considered CHE with as little as two flares a year. Trust me when I say it can make daily things like washing your hands, doing dishes, or even typing super uncomfortable. Hear me out. If you have two or more flares of hand eczema a year, that's a sign to talk to your derm. CHE is its own thing and may need a more targeted approach. Something I prescribe in clinic for patients with recurring moderate to severe hand eczema is ANZUPGO. Eczema is ANZUPGO, also known as delgocitinib. ANZUPGO is the first and only FDA-approved treatment specifically for adults with moderate to severe chronic hand eczema who are not well-controlled with or cannot use topical corticosteroids. Use of ANZUPGO along with other JAK inhibitors or strong immunosuppressants is not recommended. It's a steroid-free prescription cream that may result in patients experiencing clear skin along with relief from itch and pain. Plus, it's non-greasy and free of known sensitizers and irritants. In studies, the most common side effects reported in less than 1% of ANZUPGO treated patients include application site reactions, including pain, tingling, itching, and redness; bacterial skin infections, including finger cellulitis and nail infections; and low white blood cells. These are not all of the possible side effects of ANZUPGO. If you have or think you may have moderate to severe chronic hand eczema, I definitely recommend checking out anzupgo.com to learn more and making an appointment with a dermatologist to see if it could be a good fit for you. Stay tuned for important safety information. ANZUPGO is for use on the skin only. Do not use in or on your eyes, mouth, or vagina. What is the most important information I should know about ANZUPGO? ANZUPGO may increase your risk of infections because it contains delgocitinib, a type of medicine called a JAK inhibitor that can affect your immune system. Serious infections (including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses) have happened with JAK inhibitors. Some people have been hospitalized or died. Do not use ANZUPGO if you have an active, serious infection. Do not start ANZUPGO if you have any infection unless your healthcare provider says it's okay. You may be more likely to get shingles (herpes zoster) or eczema herpeticum (painful, blistering rash) during treatment. Before using ANZUPGO: Tell your healthcare provider if you: are being treated for an infection or have an infection that does not go away or that keeps coming back; have TB or were in close contact with someone with TB; have had shingles; have had hepatitis B or C; have symptoms of infection such as fever, chills, sweating, muscle aches, cough/shortness of breath, blood in phlegm, weight loss, warm/red/painful skin or sores, diarrhea or stomach pain, burning when urinating or urinating more often, or feeling very tired. After starting ANZUPGO: Call your healthcare provider right away if you have signs of infection. Your provider may stop ANZUPGO until the infection is controlled. ANZUPGO may increase the risk of certain skin cancers. Your healthcare provider will check your skin during treatment. Avoid sunlamps, limit sun, wear protective clothing, and use broad-spectrum sunscreen. Tell your healthcare provider if you have ever had any type of cancer. It is not known if ANZUPGO has the same risks as other JAK inhibitors. Increased risk of death (all causes) happened in people 50+ with at least one heart disease risk factor taking a JAK inhibitor for rheumatoid arthritis (RA) compared with TNF blockers. ANZUPGO is not for use in RA. Oral or other topical JAK inhibitors have also caused increased cholesterol. Low blood sugar in diabetics has happened after taking oral JAK inhibitors. Before using ANZUPGO: Tell your healthcare provider if you: have an infection; have recently received or are scheduled to receive a vaccine. Do not receive live vaccines right before starting, during treatment, or right after treatment with ANZUPGO; are pregnant or plan to become pregnant (it is not known if ANZUPGO will harm your unborn baby); are or plan to breastfeed (it is not known if ANZUPGO passes into breast milk). Avoid touching the nipple/area around it right after applying ANZUPGO to your hands and wrists. The most common side effects were application site reactions, including pain, tingling, itching, and redness; bacterial skin infections, including finger cellulitis and nail infections; and low white blood cells. These are not all of the possible side effects of ANZUPGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please see full Prescribing Information and Medication Guide.